Oculis (NASDAQ:OCS – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.28, FiscalAI reports. Oculis had a negative return on equity of 45.58% and a negative net margin of 6,777.18%.The business had revenue of $0.38 million during the quarter, compared to analyst estimates of $0.22 million.
Oculis Stock Up 2.4%
Shares of NASDAQ:OCS traded up $0.30 during trading on Friday, hitting $12.68. The company’s stock had a trading volume of 370,877 shares, compared to its average volume of 314,551. Oculis has a fifty-two week low of $10.52 and a fifty-two week high of $34.47. The business has a 50 day moving average price of $12.17 and a two-hundred day moving average price of $22.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18. The company has a market capitalization of $735.19 million, a PE ratio of -7.29 and a beta of 0.51.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. SR One Capital Management LP grew its stake in Oculis by 98.8% during the 4th quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after purchasing an additional 318,522 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in Oculis in the 4th quarter valued at about $9,862,000. Alyeska Investment Group L.P. raised its position in Oculis by 152.3% in the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after purchasing an additional 200,000 shares in the last quarter. Woodline Partners LP boosted its stake in shares of Oculis by 65.8% in the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after buying an additional 33,265 shares during the period. Finally, Alps Advisors Inc. purchased a new position in shares of Oculis in the 4th quarter valued at about $938,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Check Out Our Latest Research Report on Oculis
About Oculis
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Oculis
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
